Our rapid testing solutions not only add a layer of confidence to your employees but can act as part of a risk mitigation strategy to protect your business continuity and help keep your business running.
Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.
Thomas Schinecker
Chief Executive Officer of Roche Diagnostics
Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic.
Around the world, we are working with urgency, passion and purpose each and every day to deliver high-quality tests that are essential for healthcare systems and patients alike.
Roche analysers have assisted our customers in fast-tracking test results for COVID-19 samples, taking pressure off pathology staff. Roche Diagnostics Australia is continually committed to providing our customers with solutions to manage the pandemic response.
Reliable SARS-CoV-2 antigen test results in just 15 minutes.
Rapid antigen testing continues to play a critical role in managing the COVID-19 pandemic and forms part of our commitment to keeping Aussies safe.
For more information visit:
COVID-19 Rapid Antigen Self-Test (for home use)
COVID-19 Rapid Antigen Point of Care (POC) tests (for professional use)
The COVID-19 Rapid Antigen Self-Test (for home use) is intended for unsupervised testing in the home or other environment.
The COVID-19 Rapid Antigen Point of Care (POC) tests (for professional use) are intended for use at the point of care and must be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results. These tests must not be supplied for the purpose of self-testing.
Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained).
Follow current government health messaging regarding polymerase chain reaction (PCR) testing requirements.
The cobas® SARS-CoV-2 & Influenza A/B Assay is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2., influenza A, and influenza B in nasopharyngeal and nasal swabs from patients suspected of respiratory viral infection.
The test is run on Roche's molecular point-of-care PCR testing solution, the cobas® Liat® System, and has been included on the ARTG.
All trademarks used or mentioned are protected by law.
The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.
The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.
Our rapid testing solutions not only add a layer of confidence to your employees but can act as part of a risk mitigation strategy to protect your business continuity and help keep your business running.
The COVID-19 Rapid Antigen Point of Care (POC) tests (for professional use) are intended for use at the point of care and must be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results. These tests must not be supplied for the purpose of self-testing.
Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained).
Follow current government health messaging regarding polymerase chain reaction (PCR) testing requirements.
The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.
The cobas® SARS-CoV-2 & Influenza A/B Test is a real-time RT-PCR test intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in nasal or nasopharyngeal swab samples collected from patients.
Both tests have been included on the Australian Register of Therapeutic Goods (ARTG) and can run on Roche's fully automated cobas® 6800 and cobas® 8800 Systems.
If you would like further information concerning the products listed, please contact your local Roche Diagnostics Australia representative.
All trademarks used or mentioned are protected by law.